Landscape of helper and regulatory antitumour CD4+ T cells in melanoma-Reference-Cited by-同舟云学术

Landscape of helper and regulatory antitumour CD4+ T cells in melanoma

Published:2022-05-04 Issue:7910 Volume:605 Page:532-538
ISSN:0028-0836
Container-title:Nature
language:en
Short-container-title:Nature

Author:

Oliveira Giacomo^ORCID,Stromhaug Kari,Cieri Nicoletta^ORCID,Iorgulescu J. Bryan^ORCID,Klaeger Susan^ORCID,Wolff Jacquelyn O.,Rachimi Suzanna,Chea Vipheaviny^ORCID,Krause Kate,Freeman Samuel S.^ORCID,Zhang Wandi,Li Shuqiang,Braun David A.^ORCID,Neuberg Donna^ORCID,Carr Steven A.,Livak Kenneth J.^ORCID,Frederick Dennie T.^ORCID,Fritsch Edward F.,Wind-Rotolo Megan,Hacohen Nir^ORCID,Sade-Feldman Moshe^ORCID,Yoon Charles H.^ORCID,Keskin Derin B.,Ott Patrick A.^ORCID,Rodig Scott J.,Boland Genevieve M.,Wu Catherine J.^ORCID

Publisher

Springer Science and Business Media LLC

Subject

Multidisciplinary

Link

https://www.nature.com/articles/s41586-022-04682-5.pdf

Reference49 articles.

1. Sallusto, F. & Lanzavecchia, A. Heterogeneity of CD4+ memory T cells: functional modules for tailored immunity. Eur. J. Immunol. 39, 2076–2082 (2009).

2. Swain, S. L., McKinstry, K. K. & Strutt, T. M. Expanding roles for CD4+ T cells in immunity to viruses. Nat. Rev. Immunol. 12, 136–148 (2012).

3. Sade-Feldman, M. et al. Defining T cell states associated with response to checkpoint immunotherapy in melanoma. Cell 175, 998–1013.e20 (2018).

4. Yost, K. E. et al. Clonal replacement of tumor-specific T cells following PD-1 blockade. Nat. Med. 25, 1251–1259 (2019).

5. Wu, T. D. et al. Peripheral T cell expansion predicts tumour infiltration and clinical response. Nature 579, 274–278 (2020).

Cited by 90 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Advances in Vaccines for Melanoma;Hematology/Oncology Clinics of North America;2024-10

2. Participation of T cells in generating immune protection against cancers;Pathology - Research and Practice;2024-10

3. CD4+ T cells in antitumor immunity;Trends in Cancer;2024-09

4. Neoadjuvant PARPi or chemotherapy in ovarian cancer informs targeting effector Treg cells for homologous-recombination-deficient tumors;Cell;2024-09

5. Benefit delayed immunosenescence by regulating CD4⁺T cells: A promising therapeutic target for aging‐related diseases;Aging Cell;2024-08-18